US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biomarin Pharmaceutical

59.17

+0.35000.60%

Post-market: 59.170.00000.00%17:18 EDT

Volume:1.25M

Turnover:73.78M

Market Cap:11.35B

PE:26.81

High:59.62

Open:58.44

Low:58.00

Close:58.82

Loading ...

Overview Company News Filings

NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why

Zacks.com featured highlights include BioMarin, Amazon.com, Leidos and The Ensign

J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use

These 4 Stocks Boast Impressive Interest Coverage Ratio

Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study

Earnings are growing at BioMarin Pharmaceutical (NASDAQ:BMRN) but shareholders still don't like its prospects

Simply Wall St.

BioMarin Pharmaceutical Inc. (BMRN) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025

NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts

ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate

InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug

Kymera Provides Pipeline Objectives for 2025, Stock Gains

Centene Expands Care in Hawaii With a Residential Program

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

Bernstein Remains a Buy on BioMarin Pharmaceutical (BMRN)

BioMarin stock undervalued at current levels, says JPMorgan

BRIEF-Biomarin Announces Legal Action Against Ascendis Pharma A/S In European Unified Patent Court

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BMRN/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BMRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMRN\",,,,,undefined,":{"symbol":"BMRN","market":"US","secType":"STK","nameCN":"Biomarin Pharmaceutical","latestPrice":59.17,"timestamp":1744920000000,"preClose":58.82,"halted":0,"volume":1247162,"hourTrading":{"tag":"盘后","latestPrice":59.17,"preClose":59.17,"latestTime":"17:18 EDT","volume":102473,"amount":6063332.84,"timestamp":1744924699909},"delay":0,"floatShares":179368327,"shares":191754170,"eps":2.207261,"marketStatus":"Market Closed","change":0.35,"latestTime":"04-17 16:00:00 EDT","open":58.44,"high":59.62,"low":58,"amount":73777664.02328001,"amplitude":0.027542,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.207261,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":932702400000,"exchange":"NASDAQ","adjPreClose":58.82,"preHourTrading":{"tag":"盘前","latestPrice":58.56,"preClose":58.82,"latestTime":"09:29 EDT","volume":472,"amount":27643.230352000002,"timestamp":1744896599999},"postHourTrading":{"tag":"盘后","latestPrice":59.17,"preClose":59.17,"latestTime":"17:18 EDT","volume":102473,"amount":6063332.84,"timestamp":1744924699909},"volumeRatio":0.659425538850371,"impliedVol":0.4459,"impliedVolPercentile":0.9522},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMRN\",,,,,undefined,":{"symbol":"BMRN","floatShares":179368327,"roa":"5.15%","roe":"8.05%","lyrEps":2.246307,"volumeRatio":0.659425538850371,"shares":191754170,"dividePrice":0,"high":59.62,"amplitude":0.027542,"preClose":58.82,"low":58,"week52Low":52.93,"pbRate":"2.01","psRate":"3.98","week52High":94.85,"institutionHeld":0.9275,"latestPrice":59.17,"eps":2.207261,"divideRate":0,"volume":1247162,"delay":0,"ttmEps":2.207261,"open":58.44,"prevYearClose":65.73,"prevWeekClose":56.82,"prevMonthClose":70.69,"prevQuarterClose":70.69,"fiveDayClose":56.32,"twentyDayClose":71.6,"sixtyDayClose":62.02,"earningDate":1746028800000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMRN\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2506304692","title":"NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2506304692","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506304692?lang=en_us&edition=fundamental","pubTime":"2025-01-27 22:52","pubTimestamp":1737989520,"startTime":"0","endTime":"0","summary":"Shares of Novo Nordisk NVO gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage study of its investigational candidate, amycretin, in 125 overweight/obese patients. Amycretin is NVO’s unimolecular GLP-1 and amylin receptor agonist intended for once-weekly subcutaneous administration.The phase Ib/IIa study evaluated the safety, tolerability, pharmacokinetics and proof-of-conceptof three doses of amycretin in obesity patients for a total treatment duration of up to 36 weeks.Per Novo Nordisk, the study's primary safety endpoint was met as amycretin demonstrated a safety profileconsistent with incretin-based therapies. Treatment-related adverse events were mostly mild to moderate in severity.NVO shares have plunged 21.7% in the past three months compared with the industry’s 12.2% decline.Detailed Results From the Obesity Study of NVO’s Amycretin. Some better-ranked stocks from the sector areCastle BiosciencesCSTL, BioMarin Pharmaceutical BMRN ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvo-stock-rises-obesity-drug-145200349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVO","BK4599","LU0154236417.USD","BK4585","BK4196","BK4548","IE00B19Z3B42.SGD","BK4566","IE00B7SZLL34.SGD","BK4588","BK4532","LU1093756168.USD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","IE0002270589.USD","IE00BKVL7J92.USD","ALNY","LU1093756325.SGD","BK4139","CSTL","BK4007","BMRN"],"gpt_icon":1},{"id":"2506046113","title":"Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2506046113","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506046113?lang=en_us&edition=fundamental","pubTime":"2025-01-27 22:45","pubTimestamp":1737989113,"startTime":"0","endTime":"0","summary":"Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.Why This 1 Growth Stock Should Be On Your Watchlist. Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time.San Rafael, CA-based BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for life-threatenin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-biomarin-pharmaceutical-bmrn-144513900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BMRN","BK4566","IE00B19Z3581.USD","IE00B7SZLL34.SGD","IE0002270589.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2506893089","title":"Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2506893089","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506893089?lang=en_us&edition=fundamental","pubTime":"2025-01-24 23:56","pubTimestamp":1737734160,"startTime":"0","endTime":"0","summary":"Shares of Anavex Life Sciences AVXL, a clinical-stage biotech making medicines to treat central nervous system  diseases, have skyrocketed 94.7% in the past three months due to recent pipeline successes.Anavex Life Sciences’ clinical developmental pipeline includes two candidates, ANAVEX 2-73  and ANAVEX 3-71. Both these candidates are being developed in separate studies across various stages of development to treat a plethora of CNS indications like Alzheimer’s disease , Parkinson’s disease and schizophrenia, among others.AVXL shares have rallied 53.6% in the past year against the industry’s 12.4% decline.Upbeat Initial Data From AVXL’s Schizophrenia Study. In October 2024, Anavex Life Sciences reported positive initial biomarker results from Part A of an ongoing mid-stage study of ANAVEX 3-71 for schizophrenia. This multiple ascending dose portion of the phase II ANAVEX 3-71-SZ-001 study, evaluated two oral, daily doses of the candidate  in 16 patients for 10 days.The MAA submission ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/anavex-life-sciences-stock-skyrockets-155600615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","IE00B7SZLL34.SGD","BK4215","BMRN","BK4196","CNS","BK4135","ALNY","CSTL","IE00B19Z3581.USD","AVXL","BK4139","BK4566","MAA","BK4585","IE0002270589.USD","IE00B19Z3B42.SGD","BK4548"],"gpt_icon":0},{"id":"2505044214","title":"CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2505044214","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505044214?lang=en_us&edition=fundamental","pubTime":"2025-01-24 00:19","pubTimestamp":1737649140,"startTime":"0","endTime":"0","summary":"Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 , a cardiac myosin inhibitor, for treating heart failure patients. The intended patient population includes those with symptomatic heart failure with preserved ejection fraction  with left ventricular ejection fraction  ≥60%.Cytokinetics plans to enroll approximately 60 HFpEF patients in the phase II AMBER-HFpEF study who will receive CK-586 or placebo in three dose escalation cohorts. In the past three months, CYTK shares have lost 10.6% compared with the industry’s 8.7% decline.Cytokinetics is developing its lead investigational candidate, aficamten, a novel, oral and small-molecule cardiac myosin inhibitor, to reduce the hypercontractility associated withhypertrophic cardiomyopathy . A regulatory filing for aficamten to treat obstructive HCM is currently under review by the FDA. A final decision from the regulatory body is expected on Sept. 26, 2025. T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytk-stock-rises-enrollment-begins-161900028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","CTMX","HCM","IE00B19Z3B42.SGD","BK4531","CSTL","IE00B7SZLL34.SGD","BMRN","BK4007","BK4585","BK4566","BK4196","BK4139","CYTK","IE0002270589.USD","IE00B19Z3581.USD","BK4505"],"gpt_icon":0},{"id":"2505489620","title":"Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2505489620","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505489620?lang=en_us&edition=fundamental","pubTime":"2025-01-23 22:13","pubTimestamp":1737641580,"startTime":"0","endTime":"0","summary":"Shares of Keros Therapeutics KROS, a clinical-stage biotech, have plunged 80.9% in the past three months. The massive decline was primarily due to the company’s voluntary decision to halt dosing in the ongoing mid-stage study of its pipeline candidate, cibotercept , to treat patients with pulmonary arterial hypertension , a kind of lung disease.Keros Therapeutics’ decision was based on unexpected adverse pericardial effusion events that were observed during the study's safety review by an independent data monitoring committee . Cibotercept is an investigational modified ActRIIB fusion protein.The phase II TROPOSstudy is evaluating three doses of cibotercept  in combination with background therapy to treat PAH patients. After consulting with the DMC, Keros Therapeutics initially chose to suspend dosing in the 3 mg/kg and 4.5 mg/kg treatment arms of the TROPOS study while continuing dosing in the 1.5 mg/kg arm. However, earlier this month, the company announced the suspension of dosing i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keros-therapeutics-stock-plunges-81-141300812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4566","CTMX","IE00B7SZLL34.SGD","IE0002270589.USD","LENZ","BK4139","CSTL","BMRN","BK4196","KROS"],"gpt_icon":0},{"id":"2505067626","title":"Zacks.com featured highlights include BioMarin,  Amazon.com, Leidos and The Ensign","url":"https://stock-news.laohu8.com/highlight/detail?id=2505067626","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505067626?lang=en_us&edition=fundamental","pubTime":"2025-01-23 16:11","pubTimestamp":1737619860,"startTime":"0","endTime":"0","summary":"Chicago, IL – January 23, 2025 – Stocks in this week’s article are — BioMarin Pharmaceutical Inc. BMRN, Amazon.com, Inc. AMZN, Leidos Holdings, Inc. LDOS and The Ensign Group, Inc. ENSG.Relying solely on stock price movements without understanding the company’s fundamentals can cause investors to lose money. Investors must carefully review a company's financial health to make informed decisions, especially in today’s unpredictable market.While sales and earnings are often the go-to metrics, they can sometimes be misleading and may not show whether a company has the financial strength to cover its obligations. This is where the coverage ratio holds the key — a higher ratio signals that a company is more capable of meeting its financial commitments.Debt, which is crucial to financing operations for the majority of companies, comes at a cost called interest. Interest expense has a direct bearing on the profitability of a company. The company’s creditworthiness depends on how effectively i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-com-featured-highlights-biomarin-081100937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053666078.USD","LU0980610538.SGD","LU0345769631.USD","ENSG","LU0128525929.USD","LU0234570918.USD","LU1069344957.HKD","LU1084165304.USD","LU0689472784.USD","LU0708994859.HKD","LU1803068979.SGD","LU2462157665.USD","BK4139","LU0158827948.USD","IE00B775H168.HKD","LU0345768153.USD","LU0077335932.USD","LU0109392836.USD","LU1267930573.SGD","SGXZ51526630.SGD","LU1267930490.SGD","LU0198837287.USD","LU1037948897.HKD","LU2361045086.USD","LDOS","LU2063271972.USD","IE00B19Z8X17.USD","USAW.SI","BMRN","SG9999017495.SGD","LU1435385759.SGD","LU2552382132.HKD","IE00B1XK9C88.USD","LU1235294995.USD","LU2077746001.SGD","LU2023250330.USD","SGXZ81514606.USD","LU2065171402.SGD","AMZN","IE0004086264.USD","EBIT","LU0354030438.USD","LU0158827781.USD","LU0345769128.USD","LU0417517546.SGD","LU0943347566.SGD","LU1988902786.USD","LU2211815571.USD","IE0005OL40V9.USD","LU2242649171.HKD"],"gpt_icon":1},{"id":"2505727779","title":"J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2505727779","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505727779?lang=en_us&edition=fundamental","pubTime":"2025-01-23 00:15","pubTimestamp":1737562500,"startTime":"0","endTime":"0","summary":"Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application , seeking approval for Spravato  as a monotherapy for adults living with treatment-resistant depression .Spravato is presently approved in combination with an oral antidepressant to treat adults with TRD and depressive symptoms in adults with major depressive disorder  with acute suicidal ideation or behavior.Following the latest nod, Spravato became the first and only monotherapy for treating MDD in adults who have had an inadequate response to at least two oral antidepressants and are considered to have TRD.In the past year, shares of J&J have lost 7.3% compared with the industry’s decline of 5.1%.More on the Latest Nod for JNJ's Spravato as Monotherapy. The latest FDA nod for Spravato was based on data from a double-blind, multicenter, placebo-controlled study.In the past 60 days, estimates for BioMarin’s earnings per share have increased from $3.94 to $4.02 for 2025. In the past year, sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/j-js-depression-drug-spravato-161500318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BVYPNV92.GBP","LU1732800096.USD","IE00B19Z3581.USD","SG9999002232.USD","LU1221951129.SGD","LU1244550494.USD","BK4559","LU1718418525.SGD","LU0114720955.EUR","LU1066051811.HKD","CSTL","IE00BVYPNW00.USD","LU0122379950.USD","LU2133065610.SGD","LU2089984988.USD","LU0234570918.USD","LU2468319806.SGD","LU0792757196.USD","LU1732799900.SGD","BK4534","LU0203347892.USD","LU0795875086.SGD","JNJ","LU0234572021.USD","LU0795875169.SGD","LU1066051225.USD","LU1261432733.SGD","IE00BFTCPJ56.SGD","BK4550","LU0289739699.SGD","BK4504","LU1066051498.USD","LU1430594728.SGD","IE00BJT1NW94.SGD","LU2602419157.SGD","LU1506573853.SGD","BK4139","IE0034235303.USD","IE0009355771.USD","BK4566","VYGR","LU0345770308.USD","IE00BGHQF631.EUR","LU1929549753.HKD","BMRN","BK4532","LU0882574055.USD","LU1280957306.USD","LU0912757837.SGD","LU1585245621.USD"],"gpt_icon":1},{"id":"2505377323","title":"These 4 Stocks Boast Impressive Interest Coverage Ratio","url":"https://stock-news.laohu8.com/highlight/detail?id=2505377323","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505377323?lang=en_us&edition=fundamental","pubTime":"2025-01-22 23:19","pubTimestamp":1737559140,"startTime":"0","endTime":"0","summary":"The interest coverage ratio is used to determine how effectively a company can pay interest charges on its debt.Debt, which is crucial to financing operations for the majority of companies, comes at a cost called interest. Interest expense has a direct bearing on the profitability of a company. The company’s creditworthiness depends on how effectively it meets its interest obligations. Therefore, the interest coverage ratio is one of the important criteria to factor in before making any investment decision.Interest Coverage Ratio = Earnings before Interest & Taxes  divided by Interest Expense.The interest coverage ratio suggests how many times the interest could be paid from earnings and gauges the margin of safety a firm has for paying interest.An interest coverage ratio lower than 1 suggests that the company is unable to fulfill its interest obligations and could default on repaying debt. A company capable of generating earnings well above its interest expense can withstand financial","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/4-stocks-boast-impressive-interest-151900170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1868837136.USD","IE00B19Z3581.USD","LU2461242641.AUD","LU0029864427.USD","IE00B3SWFQ91.USD","LU2054465674.USD","LU0889565833.HKD","LU0251132253.USD","IE00B5949003.HKD","LU0823434583.USD","SG9999015986.USD","ENSG","LU0211328371.USD","LU1366333091.USD","LU2275660780.HKD","LU0011850046.USD","LU1244550221.USD","LU0354030438.USD","LU2125154778.USD","BK4535","LU0417517546.SGD","BK4548","LU2417539215.USD","BK4185","LU2552382215.SGD","LU0310799852.SGD","LU1066053197.SGD","BK4139","GB00BDT5M118.USD","IE0004445015.USD","LU0345770993.USD","IE0034235303.USD","BK4123","LU0353189763.USD","LU1868836914.USD","LU1267930730.SGD","IE00BK4W5L77.USD","LU2463028550.USD","LDOS","LU2092627202.USD","LU0642271901.SGD","BMRN","LU0708994859.HKD","LU0256863902.USD","EBIT","USAW.SI","AMZN","IE00BJTD4N35.SGD","BK4592","LU1244550577.SGD"],"gpt_icon":1},{"id":"2505204653","title":"Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2505204653","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505204653?lang=en_us&edition=fundamental","pubTime":"2025-01-21 23:43","pubTimestamp":1737474180,"startTime":"0","endTime":"0","summary":"NanobiotixNBTX shares were up around 13% during the pre-market hours on Tuesday after the company announced that it has initiated dosing in a mid-stage study evaluating a potential first-in-class radioenhancer, JNJ-1900 , to treat lung cancer patients. The candidate was added to Nanobiotix’s pipeline following a licensing deal for the global co-development and commercialization with pharma bigwig, Johnson & Johnson JNJ, in 2023.The company stated that it has dosed the first patient with JNJ-1900 in the phase II CONVERGE study to treat patients with Stage 3 unresectable non-small cell lung cancer . The eligibility criteria for this study include NSCLC patients receiving standard-of-care chemoradiation followed by consolidation immunotherapy with AstraZeneca’s Imfinzi . Per the global licensing agreement with Nanobiotix, Johnson & Johnson is responsible for funding the CONVERGE study.Nanobiotix’s pipeline comprises only JNJ-1900, which is being evaluated across multiple solid tumor indic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanobiotix-stock-gains-dosing-begins-154300753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","LU0640476718.USD","LU0289739699.SGD","LU2347655156.SGD","IE00B3PB1722.GBP","LU0122379950.USD","LU2602419157.SGD","BK4139","IE00BDGV0183.EUR","BMRN","LU1244550494.USD","LU1430594728.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE00BVYPNW00.USD","LU1023059063.AUD","LU0345769128.USD","LU1935042991.SGD","LU0889566641.SGD","BK4568","LU1244550221.USD","LU1032955483.USD","LU1066051811.HKD","IE00B42XCP33.USD","CSTL","IE00BGHQF631.EUR","LU1778281490.HKD","LU0882574055.USD","LU0234572021.USD","LU0795875169.SGD","SSI","NBTX","IE0034235303.USD","LU1894683348.USD","LU1732800096.USD","IE0002270589.USD","LU1066051498.USD","LU0792757196.USD","LU1196500208.SGD","BK4588","LU1032466523.USD","IE00BJT1NW94.SGD","LU0203345920.USD","BK4550","LU0320765646.SGD","LU1674673428.USD","JNJ","SG9999002224.SGD","LU1929549753.HKD","LU1732799900.SGD"],"gpt_icon":0},{"id":"2505156247","title":"Earnings are growing at BioMarin Pharmaceutical (NASDAQ:BMRN) but shareholders still don't like its prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2505156247","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505156247?lang=en_us&edition=fundamental","pubTime":"2025-01-21 18:24","pubTimestamp":1737455079,"startTime":"0","endTime":"0","summary":"Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if you buy individual stocks, you can do both better or worse than that. For example, the BioMarin Pharmaceutical Inc.  share price is down 34% in the last year. That falls noticeably short of the market return of around 26%. Even if shareholders bought some time ago, they wouldn't be particularly happy: the stock is down 27% in three years. Shareholders have had an even rougher run lately, with the share price down 12% in the last 90 days.After losing 3.6% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. By comparing earnings per share  and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.During the unfortunate twelve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/earnings-growing-biomarin-pharmaceutical-nasdaq-102439511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","NDAQ","BMRN"],"gpt_icon":0},{"id":"2505326060","title":"BioMarin Pharmaceutical Inc. (BMRN) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505326060","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505326060?lang=en_us&edition=fundamental","pubTime":"2025-01-21 10:57","pubTimestamp":1737428256,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Under-the-Radar Stocks with Massive Upside for 2025.In this article, we are going to take a look at where BioMarin Pharmaceutical Inc.  stands against other under-the-radar stocks.Investing in under-the-radar stocks can be a savvy move for those looking to diversify their portfolios and potentially reap significant rewards. These lesser-known companies often fly under the radar of mainstream investors, which can result in undervalued stock prices. Under-the-radar stocks can be found in various sectors, from emerging technologies to niche industries, and are often characterized by their small market capitalization, limited analyst coverage, and low trading volumes.The impressive returns achieved by lesser-known hedge funds can be attributed to their bold investment strategies, which included a focus on under-the-radar stocks. By investing in these hidden gems, these funds were able to capitalize on undervalued opportunities and reap significant rewa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biomarin-pharmaceutical-inc-bmrn-stock-025736303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","SQQQ","QLD","USAW.SI","USJW.SI","TSYW.SI","NQmain","IE0002270589.USD","IE00B19Z3B42.SGD","TQQQ","BMRN","BK4566","QID","NVIW.SI","IE00B19Z3581.USD",".IXIC","IE00B7SZLL34.SGD","BK4139","PSQ"],"gpt_icon":1},{"id":"2505233741","title":"NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts","url":"https://stock-news.laohu8.com/highlight/detail?id=2505233741","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505233741?lang=en_us&edition=fundamental","pubTime":"2025-01-20 23:53","pubTimestamp":1737388380,"startTime":"0","endTime":"0","summary":"Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular semaglutide medicines as one of the 15 additional drugs covered under Medicare Part D for the second round of price negotiations in 2025. Novo Nordisk markets its semaglutide medicines as Ozempic pre-filled pens and Rybelsus oral tablets for type II diabetes  and Wegovy injections for weight management.Any price reduction resulting from the impending negotiations will become effective in 2027.For continued coverage of its semaglutide medicines under Medicare, NVO has until Feb. 28, 2025, to decide if it will participate in negotiations or pay a large tax on U.S. sales of the drugs. Either way, investors anticipate a decline in the company's profit margins resulting in the stock price decline. The Inflation Reduction Act allows Medicare to negotiate the prices of certain prescription drugs to make them more affordable for seniors and people with disabilities.Analysis of th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvo-stock-down-medicare-selects-155300223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0094547139.USD","LU1057294990.SGD","LU1551013425.SGD","SGXZ99366536.SGD","IE0009355771.USD","LU1712237335.SGD","SG9999001176.SGD","NVO","IE00B4R5TH58.HKD","LU1868837136.USD","LU2361045086.USD","IE00BKVL7J92.USD","LU0672654240.SGD","LU1720051017.SGD","LU0640476718.USD","LU0238689110.USD","LU0198837287.USD","LU0114720955.EUR","LU1804176565.USD","LU0058720904.USD","LU0109391861.USD","LU0943347566.SGD","LU1280957306.USD","BK4516","SG9999015945.SGD","IE0002270589.USD","LU0471298777.SGD","IE00BK4W5M84.HKD","LU2063271972.USD","LU0466842654.USD","BK4566","LU1868836591.USD","LU1093756168.USD","LU0096364046.USD","LU2237443549.SGD","LU2491050154.USD","BK4534","LU1035775433.USD","LU2237438978.USD","LU2264538146.SGD","LU0820561818.USD","LU0320765059.SGD","LLY","CSTL","BMRN","LU0006306889.USD","LU0256863811.USD","SG9999015952.SGD","LU1983299246.USD","LU0708995401.HKD"],"gpt_icon":1},{"id":"2504195429","title":"ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2504195429","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504195429?lang=en_us&edition=fundamental","pubTime":"2025-01-17 22:24","pubTimestamp":1737123840,"startTime":"0","endTime":"0","summary":"Tab-cel, the company’s novel T-cell immunotherapy, is already marketed in the EU under the brand name, Ebvallo, by Atara’s partner Pierre Fabre under an exclusive commercialization and license agreement.EBV+ PTLD is a rare hematologic malignancy  with a high mortality rate and occurs after patients undergo transplantation when their T-cell immune responses are compromised by immunosuppression.In the past three months, Atara shares have lost 16.8% compared with the industry’s 12.2% decline.More on the FDA’s CRL Issuance Against ATRA’s Ebvallo. Atara is eligible to receive a $60 million milestone payment from Pierre Fabre upon FDA approval of the Ebvallo BLA, providing a critical cash infusion for the company. Additionally, it will be eligible for substantial double-digit tiered royalties based on net sales and further milestones tied to Ebvallo's commercial performance. However, the FDA's CRL has also delayed the milestone payment, impacting funds the company planned to allocate for sup","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atra-stock-down-fda-issues-142400167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZLL34.SGD","CSTL","IE0002270589.USD","ATRA","IE00B19Z3B42.SGD","LU0390134368.USD","IE00B19Z3581.USD","CTMX","BK4585","BK4588","BK4139","BK4566","CRL","BK4121","BMRN","BK4530","BK4196"],"gpt_icon":0},{"id":"2504433569","title":"InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2504433569","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504433569?lang=en_us&edition=fundamental","pubTime":"2025-01-16 23:49","pubTimestamp":1737042540,"startTime":"0","endTime":"0","summary":"InflaRx N.V.IFRX shares gained 7.7% on Wednesday following the European Commission's  approval of marketing authorization, under exceptional circumstances, for Gohibic  to treat adult patients with acute respiratory distress syndrome  caused by SARS-CoV-2. The targeted patient population in the EU comprises individuals receiving systemic corticosteroids as standard-of-care therapy and undergoing invasive mechanical ventilation, with or without extracorporeal membrane oxygenation.The EC’s approval makes Gohibic the first and only approved treatment for SARS-CoV-2-induced ARDS in the EU. We remind the investors that in November 2024, the advisory committee to the European Medicines Agency had adopted a positive opinion recommending approval of the drug for the above indication, under exceptional circumstances. Gohibic is a first-in-class anti-C5a monoclonal antibody.More on the EC Nod for IFRX’s COVID-19-Induced ARDS Drug. The EU approval ofInflaRx’s Gohibic for the ADRS indication is ba","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inflarx-stock-rises-8-conditional-154900009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1280957306.USD","CTMX","IE00BLSP4239.USD","LU1868837300.USD","LU1066053197.SGD","LU1066051498.USD","BNTX","IFRX","BK4581","BMRN","BK4018","BK4139","BK4196","LU0098860793.USD","IE00BWXC8680.SGD","LU0689626769.HKD","LU1868836591.USD","LU0094547139.USD","LU0061475181.USD","ARDS","IE00BBT3K403.USD","LU0640476718.USD","EC","SG9999002224.SGD","LU1430594728.SGD","BK4548","SG9999002232.USD","IE00B7SZLL34.SGD","SG9999015358.SGD","LU0320765646.SGD","LU1868837136.USD","SG9999001440.SGD","BK4551","LU2552382132.HKD","BK4533","LU2242652126.USD","IE00BLSP4452.SGD","CSTL","LU1929549753.HKD","PG","LU0124676726.USD","LU0868494617.USD","SG9999014575.USD","IE000M9KFDE8.USD","BK4201","LU2242646821.SGD","SG9999014559.SGD","LU2552382215.SGD","BK4504","BK4568"],"gpt_icon":0},{"id":"2503749996","title":"Kymera Provides Pipeline Objectives for 2025, Stock Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2503749996","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503749996?lang=en_us&edition=fundamental","pubTime":"2025-01-16 02:30","pubTimestamp":1736965800,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. KYMR announced its business goals for 2025, along with anticipated progress on its pipeline of immunology programs.Shares of KYMR have surged 47.2% in a year against the industry’s decline of 16%.Kymera is developing KT-621, an investigational, first-in-class, once-daily oral degrader of STAT6. The candidate has demonstrated dupilumab-like activity and very good safety data in preclinical models.Kymera expects to complete this phase I study and report data in the second quarter of 2025. It will also advance the candidate in a phase lb study in AD patients in the second quarter of 2025 and report data in the fourth quarter of the year.Kymera is also evaluating KT-295, an investigational, first-in-class, once-daily oral degrader of TYK2, a member of the Janus kinase  family required for Type I IFN, IL-12 and IL-23 signaling.The company expects to file an investigational new drug application for the candidate and initiate dosing in the phase I healthy volunteer c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymera-provides-pipeline-objectives-2025-183000231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","BK4585","BK4196","BMRN","SNY","IE00B19Z3581.USD","BK4007","IE00BFXG1179.USD","BK4588","BK4139","BK4566","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","KYMR","IE0002270589.USD"],"gpt_icon":0},{"id":"2503679126","title":"Centene Expands Care in Hawaii With a Residential Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2503679126","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503679126?lang=en_us&edition=fundamental","pubTime":"2025-01-16 01:38","pubTimestamp":1736962680,"startTime":"0","endTime":"0","summary":"Centene Corporation CNC recently unveiled that its subsidiary, 'Ohana Health Plan, collaborated with the nonprofit homeless services organization on Hawaii Island, Hope Services Hawaii. The tie-up was meant to introduce a residential program offering integrated clinical care exclusively to 'Ohana Health Plan members.The transitional housing and structured support are provided through a property, which is owned by the County of Hawaii and operates under an existing lease agreement with Hope Services. It is a six-bed facility that offers emergency shelter services to the homelessness.The newly launched program emphasizes comprehensive, long-term clinical care and case management, with an average residency of one year. The services include providing behavioral health case management, therapy and psychosocial rehabilitation facilitated by licensed clinicians, medication management overseen by an Advanced Practice Registered Nurse and housing case management support. Additionally, a multidi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/centene-expands-care-hawaii-residential-173800099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0648000940.SGD","IE0002270589.USD","LU2065171402.SGD","CNC","BK4154","LU0130518102.USD","LU2362541273.HKD","LU2362541513.USD","BK4566","LU0980610538.SGD","LU2065170008.USD","BK4121","LU0477156797.USD","IE0034390439.USD","LU1201861249.SGD","IE00B19Z3B42.SGD","MEDP","IE00B19Z3581.USD","BK4585","BK4588","BK4139","IE00B19Z6F94.USD","LU1699723380.USD","LU2065171311.SGD","IE0034235188.USD","BMRN","LU0130102774.USD","LU2065169927.USD","LU2362540622.SGD","LU1201861165.SGD","LU1291159041.SGD","LU0477156953.USD","ENOV","LU2065732104.USD","IE00B7SZLL34.SGD","LU0648001328.SGD","BK4082","LU1989771016.USD","LU0130103400.USD","LU0130517989.USD"],"gpt_icon":0},{"id":"2503950564","title":"5 Biotech Stocks Worth Adding to Your Portfolio in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503950564","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503950564?lang=en_us&edition=fundamental","pubTime":"2025-01-14 23:02","pubTimestamp":1736866920,"startTime":"0","endTime":"0","summary":"The macroenvironment in 2025 looks grim as signs of a slowdown in the economy set in. The biotech industry experienced a choppy ride in 2024, and the same is likely in store in 2025. Given the continuous need for innovative medical treatments, irrespective of the state of the economy, the biotech industry will continue to grab investors’ interest despite the inherent volatility and uncertain macroeconomic environment.M&A activity is likely to accelerate in 2025 with a change in administration and expected deregulation. Pharma and biotech bigwigs always look to bolster their product portfolios and pipelines through collaborations and buyouts. While oncology and immuno-oncology companies have always been acquisition targets, those with obesity drugs in their portfolio/pipeline and gene-editing companies hold great potential. This will put the spotlight on smaller biotech companies with promising candidates in their kitty.Biotech companies like Incyte INCY, BioMarin Pharmaceutical BMRN, E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/5-biotech-stocks-worth-adding-150200564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","SDS","BK4139","BK4504","VOO","SH",".SPX","OEX","BK4581","IE0002270589.USD","BK4588","BPMC","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BK4550","SPXU","INCY","BK4585","SPY","BK4566","BK4505","BK4559","BMRN","BK4532","SSO","RCC","UPRO","OEF","IVV","EXEL","ESmain","HALO","LU0053671581.USD"],"gpt_icon":1},{"id":"2503525049","title":"Bernstein Remains a Buy on BioMarin Pharmaceutical (BMRN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503525049","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503525049?lang=en_us&edition=fundamental","pubTime":"2025-01-14 19:31","pubTimestamp":1736854276,"startTime":"0","endTime":"0","summary":"In a report released today, William Pickering from Bernstein maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-buy-on-biomarin-pharmaceutical-bmrn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-buy-on-biomarin-pharmaceutical-bmrn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3581.USD","IE0002270589.USD","IE00B19Z3B42.SGD","BMRN","BK4139","BK4566","IE00B7SZLL34.SGD"],"gpt_icon":0},{"id":"2503537141","title":"BioMarin stock undervalued at current levels, says JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2503537141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503537141?lang=en_us&edition=fundamental","pubTime":"2025-01-14 03:50","pubTimestamp":1736797833,"startTime":"0","endTime":"0","summary":"JPMorgan reiterated an Overweight rating and $109 price target on BioMarin (BMRN) Pharmaceuticals following the company’s presentation at the JPMor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biomarin-stock-undervalued-at-current-levels-says-jpmorgan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biomarin-stock-undervalued-at-current-levels-says-jpmorgan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0215105999.USD","LU0971096721.USD","IE00B1BXHZ80.USD","IE00BFXG1179.USD","LU1894683264.USD","BK4207","LU0149725797.USD","LU0320765646.SGD","SG9999002232.USD","LU0310799852.SGD","LU1548497426.USD","LU0048584097.USD","LU1496350171.SGD","BMRN","BK4550","IE00B775SV38.USD","LU1917777945.USD","LU1914381329.SGD","LU0882574139.USD","LU1720051108.HKD","IE00BJTD4V19.USD","LU2357305700.SGD","IE00B3S45H60.SGD","LU0203345920.USD","IE00BLSP4452.SGD","LU0208291251.USD","LU0211326755.USD","LU0267386448.USD","LU1363072403.SGD","LU1244550221.USD","IE000M9KFDE8.USD","LU0976567544.SGD","LU2430703251.USD","LU2237443465.HKD","LU1988902786.USD","LU2552382215.SGD","LU2552382132.HKD","LU1668664300.SGD","LU2505996681.GBP","LU1162221912.USD","LU2430703095.HKD","IE00BLSP4239.USD","LU0256863811.USD","IE00B1XK9C88.USD","LU1244550494.USD","LU2237443895.HKD","IE0034235295.USD","BK4588","LU2552382058.USD","LU0320765489.SGD"],"gpt_icon":0},{"id":"2503531952","title":"BRIEF-Biomarin Announces Legal Action Against Ascendis Pharma A/S In European Unified Patent Court","url":"https://stock-news.laohu8.com/highlight/detail?id=2503531952","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503531952?lang=en_us&edition=fundamental","pubTime":"2025-01-14 02:48","pubTimestamp":1736794089,"startTime":"0","endTime":"0","summary":"BRIEF-Biomarin Announces Legal Action Against Ascendis Pharma A/S In European Unified Patent CourtJan 13 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O:BIOMARIN ANNOUNCES LEGAL ACTION AGAINST ASCENDIS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O91KB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B19Z3B42.SGD","IE0002270589.USD","BMRN","IE00B19Z3581.USD","IE00B7SZLL34.SGD","BK4566"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMRN\",params:#limit:5,,,undefined,":[{"date":"2025-05-01","symbol":"BMRN","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":0.75,"defaultRemindTime":1746129600000,"name":null,"time":"Post Market","dateTimestamp":1746072000000,"actualEps":null},{"market":"US","date":"2025-02-19","symbol":"BMRN","fiscalQuarterEnding":"2024/12","expectedEps":0.55,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739941200000,"reportTimeType":"post","actualEps":0.72},{"market":"US","date":"2024-10-29","symbol":"BMRN","fiscalQuarterEnding":"2024/09","expectedEps":0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730174400000,"reportTimeType":"post","actualEps":0.74},{"market":"US","date":"2024-08-05","symbol":"BMRN","fiscalQuarterEnding":"2024/06","expectedEps":0.38,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722830400000,"reportTimeType":"post","actualEps":0.77},{"market":"US","date":"2024-04-24","symbol":"BMRN","fiscalQuarterEnding":"2024/03","expectedEps":0.37,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1713931200000,"reportTimeType":"post","actualEps":0.49}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMRN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMRN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3448,"buy":0.4483,"hold":0.2069,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4483,"analysts":29,"updateTime":1740456000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BMRN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BMRN","date":"2025-04-17","current":26.423199,"percent":0.244698,"low":-742.431892,"twenty":18.323094,"median":112.852143,"eighty":244.60049,"high":1069.125802,"avg":167.492096,"sd":259.828409,"marketCap":11278980279},"quantilePoints":[{"date":"2020-04-24","current":-737.580882,"twenty":-145.315182,"median":-112.264026,"eighty":-74.453642,"marketCap":17589828874},{"date":"2020-05-01","current":139.717537,"twenty":-146.720429,"median":-112.32011,"eighty":-74.102444,"marketCap":15928637554},{"date":"2020-05-08","current":151.00669,"twenty":-146.720429,"median":-112.32011,"eighty":-70.459717,"marketCap":17215668691},{"date":"2020-05-15","current":148.690831,"twenty":-146.720429,"median":-112.264026,"eighty":-67.95747,"marketCap":16951646881},{"date":"2020-05-22","current":154.670823,"twenty":-146.720429,"median":-112.009509,"eighty":-65.875106,"marketCap":17633401828},{"date":"2020-05-29","current":169.010114,"twenty":-146.720429,"median":-111.583861,"eighty":-65.266721,"marketCap":19268167006},{"date":"2020-06-05","current":167.82046,"twenty":-146.720429,"median":-111.430067,"eighty":-53.616205,"marketCap":19132539364},{"date":"2020-06-12","current":167.693564,"twenty":-146.720429,"median":-111.166002,"eighty":-52.32921,"marketCap":19118072416},{"date":"2020-06-19","current":196.879731,"twenty":-146.720429,"median":-110.643992,"eighty":-51.800638,"marketCap":22445470566},{"date":"2020-06-26","current":196.72111,"twenty":-146.720429,"median":-110.454206,"eighty":-51.112661,"marketCap":22427386881},{"date":"2020-07-02","current":201.099035,"twenty":-146.720429,"median":-110.047751,"eighty":-50.787838,"marketCap":22926496603},{"date":"2020-07-10","current":199.956968,"twenty":-146.720429,"median":-109.640088,"eighty":-50.663322,"marketCap":22796294067},{"date":"2020-07-17","current":203.367308,"twenty":-146.720429,"median":-109.199968,"eighty":-50.401769,"marketCap":23185093307},{"date":"2020-07-24","current":195.023871,"twenty":-146.720429,"median":-109.08296,"eighty":-50.291122,"marketCap":22233891445},{"date":"2020-07-31","current":190.043188,"twenty":-146.720429,"median":-108.761911,"eighty":-50.018415,"marketCap":21666063717},{"date":"2020-08-07","current":176.02739,"twenty":-146.720429,"median":-108.266562,"eighty":-49.711244,"marketCap":21520756675},{"date":"2020-08-14","current":175.270889,"twenty":-146.720429,"median":-107.874867,"eighty":-49.409876,"marketCap":21428268381},{"date":"2020-08-21","current":111.294641,"twenty":-146.720429,"median":-107.54787,"eighty":-49.282149,"marketCap":13606660262},{"date":"2020-08-28","current":113.297144,"twenty":-146.720429,"median":-107.159772,"eighty":-49.094704,"marketCap":13851482218},{"date":"2020-09-04","current":112.733477,"twenty":-146.720429,"median":-106.448863,"eighty":-48.818303,"marketCap":13782569372},{"date":"2020-09-11","current":106.874302,"twenty":-146.720429,"median":-105.912505,"eighty":-48.569168,"marketCap":13066238463},{"date":"2020-09-18","current":117.74715,"twenty":-146.720429,"median":-105.43525,"eighty":-48.312221,"marketCap":14395531009},{"date":"2020-09-25","current":114.795312,"twenty":-146.720429,"median":-104.968329,"eighty":-48.052471,"marketCap":14034645311},{"date":"2020-10-02","current":111.220475,"twenty":-146.720429,"median":-104.968329,"eighty":-47.767481,"marketCap":13597592783},{"date":"2020-10-09","current":116.960982,"twenty":-146.720429,"median":-104.968329,"eighty":-47.469759,"marketCap":14299415723},{"date":"2020-10-16","current":117.554316,"twenty":-146.720429,"median":-104.968329,"eighty":-47.31175,"marketCap":14371955562},{"date":"2020-10-23","current":115.002979,"twenty":-146.720429,"median":-104.968329,"eighty":-47.07446,"marketCap":14060034255},{"date":"2020-10-30","current":110.40464,"twenty":-146.720429,"median":-104.968329,"eighty":-46.453512,"marketCap":13497850504},{"date":"2020-11-06","current":16.333756,"twenty":-145.315182,"median":-104.024299,"eighty":-46.24616,"marketCap":13916768073},{"date":"2020-11-13","current":16.516158,"twenty":-144.868574,"median":-103.498065,"eighty":-45.910184,"marketCap":14072179785},{"date":"2020-11-20","current":16.181659,"twenty":-144.868574,"median":-102.889101,"eighty":-45.353548,"marketCap":13787178208},{"date":"2020-11-27","current":17.129762,"twenty":-144.868574,"median":-102.47937,"eighty":-34.458654,"marketCap":14594985226},{"date":"2020-12-04","current":16.961447,"twenty":-144.868574,"median":-101.666821,"eighty":-33.817892,"marketCap":14451576789},{"date":"2020-12-11","current":16.93588,"twenty":-144.868574,"median":-101.332926,"eighty":-32.987662,"marketCap":14429793229},{"date":"2020-12-18","current":18.930091,"twenty":-144.868574,"median":-100.855221,"eighty":-31.786506,"marketCap":16128910912},{"date":"2020-12-24","current":18.88961,"twenty":-144.868574,"median":-100.530187,"eighty":-31.699842,"marketCap":16094420276},{"date":"2020-12-31","current":18.682945,"twenty":-144.868574,"median":-100.130791,"eighty":-31.545183,"marketCap":15918336499},{"date":"2021-01-08","current":19.145278,"twenty":-144.868574,"median":-99.499409,"eighty":-31.239921,"marketCap":16312255876},{"date":"2021-01-15","current":17.677318,"twenty":-144.868574,"median":-99.011614,"eighty":-31.142754,"marketCap":15061516470},{"date":"2021-01-22","current":18.746862,"twenty":-144.868574,"median":-98.307572,"eighty":-30.998361,"marketCap":15972795399},{"date":"2021-01-29","current":17.636837,"twenty":-144.868574,"median":-97.576033,"eighty":-30.940261,"marketCap":15027025834},{"date":"2021-02-05","current":18.156695,"twenty":-144.868574,"median":-97.576033,"eighty":-30.85726,"marketCap":15469958221},{"date":"2021-02-12","current":18.544458,"twenty":-144.868574,"median":-97.576033,"eighty":-30.741472,"marketCap":15800342215},{"date":"2021-02-19","current":17.419519,"twenty":-144.868574,"median":-97.521381,"eighty":-30.612592,"marketCap":14841865573},{"date":"2021-02-26","current":16.477433,"twenty":-144.868574,"median":-95.195111,"eighty":-30.351921,"marketCap":14072205552},{"date":"2021-03-05","current":16.549346,"twenty":-144.931156,"median":-92.988484,"eighty":-30.193594,"marketCap":14133621026},{"date":"2021-03-12","current":16.344954,"twenty":-144.931156,"median":-92.037344,"eighty":-30.118727,"marketCap":13959064533},{"date":"2021-03-19","current":16.645154,"twenty":-144.931156,"median":-90.941505,"eighty":-29.706846,"marketCap":14215444382},{"date":"2021-03-26","current":16.070302,"twenty":-144.868574,"median":-89.639785,"eighty":-29.214173,"marketCap":13724504246},{"date":"2021-04-01","current":16.570636,"twenty":-144.868574,"median":-88.5032,"eighty":-28.439397,"marketCap":14151803994},{"date":"2021-04-09","current":16.408826,"twenty":-144.931156,"median":-87.602744,"eighty":-27.75353,"marketCap":14013613437},{"date":"2021-04-16","current":16.904902,"twenty":-144.931156,"median":-86.817737,"eighty":-27.498326,"marketCap":14437276592},{"date":"2021-04-23","current":16.838842,"twenty":-144.931156,"median":-86.272203,"eighty":-27.151224,"marketCap":14380859669},{"date":"2021-04-30","current":17.900998,"twenty":-144.931156,"median":-85.694758,"eighty":15.913176,"marketCap":14232904679},{"date":"2021-05-07","current":17.874568,"twenty":-144.931156,"median":-85.610935,"eighty":16.023777,"marketCap":14211889902},{"date":"2021-05-14","current":17.681503,"twenty":-144.931156,"median":-85.219763,"eighty":16.210666,"marketCap":14058386140},{"date":"2021-05-21","current":17.950414,"twenty":-144.931156,"median":-84.959558,"eighty":16.297129,"marketCap":14272194951},{"date":"2021-05-28","current":17.766543,"twenty":-144.931156,"median":-84.679572,"eighty":16.395247,"marketCap":14126000892},{"date":"2021-06-04","current":17.902148,"twenty":-144.931156,"median":-84.297713,"eighty":16.432736,"marketCap":14233819010},{"date":"2021-06-11","current":18.862875,"twenty":-144.931156,"median":-84.279085,"eighty":16.501579,"marketCap":14997682966},{"date":"2021-06-18","current":18.823802,"twenty":-144.931156,"median":-84.279085,"eighty":16.577449,"marketCap":14966616728},{"date":"2021-06-25","current":19.488036,"twenty":-144.931156,"median":-84.279085,"eighty":16.648523,"marketCap":15494742764},{"date":"2021-07-02","current":19.644327,"twenty":-144.931156,"median":-84.279085,"eighty":16.690717,"marketCap":15619007714},{"date":"2021-07-09","current":19.219125,"twenty":-144.931156,"median":-84.185949,"eighty":16.765656,"marketCap":15280933954},{"date":"2021-07-16","current":18.120495,"twenty":-144.931156,"median":-83.841344,"eighty":16.854046,"marketCap":14407424455},{"date":"2021-07-23","current":17.706785,"twenty":-144.931156,"median":-83.683013,"eighty":16.951792,"marketCap":14078487823},{"date":"2021-07-30","current":16.8013,"twenty":-144.931156,"median":-83.422231,"eighty":17.027349,"marketCap":14066283248},{"date":"2021-08-06","current":17.110693,"twenty":-144.931156,"median":-82.965863,"eighty":17.063524,"marketCap":14325311683},{"date":"2021-08-13","current":16.431784,"twenty":-144.931156,"median":-82.965863,"eighty":17.063524,"marketCap":13756919692},{"date":"2021-08-20","current":16.455874,"twenty":-144.931156,"median":-82.965863,"eighty":17.063524,"marketCap":13777088440},{"date":"2021-08-27","current":18.288928,"twenty":-144.931156,"median":-82.965863,"eighty":17.151762,"marketCap":15311746815},{"date":"2021-09-03","current":18.604292,"twenty":-144.931156,"median":-82.965863,"eighty":17.265235,"marketCap":15575774062},{"date":"2021-09-10","current":17.077843,"twenty":-144.931156,"median":-82.965863,"eighty":17.275493,"marketCap":14297808844},{"date":"2021-09-17","current":17.029662,"twenty":-144.931156,"median":-82.965863,"eighty":17.275493,"marketCap":14257471348},{"date":"2021-09-24","current":17.213624,"twenty":-144.931156,"median":-82.965863,"eighty":17.308169,"marketCap":14411487243},{"date":"2021-10-01","current":16.89826,"twenty":-144.931156,"median":-82.965863,"eighty":17.308169,"marketCap":14147459995},{"date":"2021-10-08","current":17.044992,"twenty":-144.931156,"median":-82.965863,"eighty":17.308169,"marketCap":14270306006},{"date":"2021-10-15","current":16.620127,"twenty":-144.931156,"median":-82.965863,"eighty":17.308169,"marketCap":13914602631},{"date":"2021-10-22","current":16.14927,"twenty":-144.931156,"median":-82.965863,"eighty":17.308169,"marketCap":13520395283},{"date":"2021-10-29","current":913.742979,"twenty":-144.931156,"median":-82.965863,"eighty":17.356508,"marketCap":14544047003},{"date":"2021-11-05","current":967.9689,"twenty":-144.931156,"median":-82.965863,"eighty":17.405709,"marketCap":15407160981},{"date":"2021-11-12","current":942.70851,"twenty":-144.931156,"median":-82.965863,"eighty":17.560148,"marketCap":15005091360},{"date":"2021-11-19","current":1055.053805,"twenty":-144.931156,"median":-82.965863,"eighty":17.678992,"marketCap":16793291407},{"date":"2021-11-26","current":1010.184893,"twenty":-144.931156,"median":-82.965863,"eighty":17.719077,"marketCap":16079112949},{"date":"2021-12-03","current":956.780508,"twenty":-144.931156,"median":-82.965863,"eighty":17.763785,"marketCap":15229075350},{"date":"2021-12-10","current":979.157292,"twenty":-144.931156,"median":-82.965863,"eighty":17.780334,"marketCap":15585246612},{"date":"2021-12-17","current":997.497027,"twenty":-144.931156,"median":-82.965863,"eighty":17.854801,"marketCap":15877160172},{"date":"2021-12-23","current":1051.478133,"twenty":-144.931156,"median":-82.965863,"eighty":17.921454,"marketCap":16736377443},{"date":"2021-12-31","current":1019.0664,"twenty":-144.931156,"median":-82.965863,"eighty":18.068316,"marketCap":16220479893},{"date":"2022-01-07","current":971.77526,"twenty":-144.868574,"median":-82.756306,"eighty":18.102568,"marketCap":15467746814},{"date":"2022-01-14","current":1040.635774,"twenty":-144.868574,"median":-82.756306,"eighty":18.18902,"marketCap":16563799615},{"date":"2022-01-21","current":976.38903,"twenty":-144.868574,"median":-82.756306,"eighty":18.272526,"marketCap":15541184188},{"date":"2022-01-28","current":993.806011,"twenty":-144.868574,"median":-82.756306,"eighty":18.302,"marketCap":15818410273},{"date":"2022-02-04","current":1022.296039,"twenty":-144.868574,"median":-82.756306,"eighty":18.385092,"marketCap":16271886055},{"date":"2022-02-11","current":1048.594527,"twenty":-144.868574,"median":-82.756306,"eighty":18.50696,"marketCap":16690479084},{"date":"2022-02-18","current":978.811259,"twenty":-144.868574,"median":-82.756306,"eighty":18.612353,"marketCap":15579738809},{"date":"2022-02-25","current":-223.863547,"twenty":-146.720429,"median":-83.128851,"eighty":18.645295,"marketCap":14345176092},{"date":"2022-03-04","current":-219.184373,"twenty":-148.717362,"median":-83.543308,"eighty":18.645295,"marketCap":14045334603},{"date":"2022-03-11","current":-218.207922,"twenty":-159.853208,"median":-83.818061,"eighty":18.645295,"marketCap":13982763668},{"date":"2022-03-18","current":-234.549105,"twenty":-161.293219,"median":-83.967078,"eighty":18.645295,"marketCap":15029906670},{"date":"2022-03-25","current":-226.938537,"twenty":-162.185225,"median":-84.288399,"eighty":18.645295,"marketCap":14542221441},{"date":"2022-04-01","current":-227.656515,"twenty":-163.361234,"median":-84.633004,"eighty":18.645295,"marketCap":14588229481},{"date":"2022-04-08","current":-246.955768,"twenty":-164.641244,"median":-84.986921,"eighty":18.645295,"marketCap":15824925610},{"date":"2022-04-14","current":-238.225154,"twenty":-165.041247,"median":-85.857746,"eighty":18.645295,"marketCap":15265467837},{"date":"2022-04-22","current":-232.276832,"twenty":-165.973254,"median":-88.12096,"eighty":18.645295,"marketCap":14884299384},{"date":"2022-04-29","current":382.277246,"twenty":-166.445258,"median":-90.308931,"eighty":18.664196,"marketCap":15041462794},{"date":"2022-05-06","current":372.455987,"twenty":-166.445258,"median":-89.349626,"eighty":18.760072,"marketCap":14655025704},{"date":"2022-05-13","current":365.458317,"twenty":-166.445258,"median":-89.349626,"eighty":18.859197,"marketCap":14379688400},{"date":"2022-05-20","current":374.814577,"twenty":-166.445258,"median":-89.349626,"eighty":18.955948,"marketCap":14747829142},{"date":"2022-05-27","current":380.691624,"twenty":-166.445258,"median":-89.349626,"eighty":19.066512,"marketCap":14979073327},{"date":"2022-06-03","current":364.329924,"twenty":-166.445258,"median":-89.349626,"eighty":19.178673,"marketCap":14335289516},{"date":"2022-06-10","current":352.998976,"twenty":-166.445258,"median":-89.349626,"eighty":19.261875,"marketCap":13889450727},{"date":"2022-06-17","current":357.700614,"twenty":-166.445258,"median":-89.349626,"eighty":19.519294,"marketCap":14074446075},{"date":"2022-06-24","current":408.337255,"twenty":-166.509258,"median":-86.272203,"eighty":107.93637,"marketCap":16066845973},{"date":"2022-07-01","current":399.545192,"twenty":-166.509258,"median":-84.809963,"eighty":110.39574,"marketCap":15720904673},{"date":"2022-07-08","current":418.539809,"twenty":-166.509258,"median":-84.754081,"eighty":111.051374,"marketCap":16468285878},{"date":"2022-07-15","current":409.418632,"twenty":-166.509258,"median":-83.152135,"eighty":111.935442,"marketCap":16109394903},{"date":"2022-07-22","current":400.720602,"twenty":-166.509258,"median":-83.077626,"eighty":112.591077,"marketCap":15767153510},{"date":"2022-07-29","current":404.575945,"twenty":-166.509258,"median":-81.708522,"eighty":113.113211,"marketCap":15918849695},{"date":"2022-08-05","current":327.838991,"twenty":-166.509258,"median":-34.536978,"eighty":114.110012,"marketCap":17726254245},{"date":"2022-08-12","current":325.272938,"twenty":-166.509258,"median":-34.536978,"eighty":114.976279,"marketCap":17587507734},{"date":"2022-08-19","current":318.464838,"twenty":-166.509258,"median":-34.536978,"eighty":115.685314,"marketCap":17219393812},{"date":"2022-08-26","current":312.187472,"twenty":-166.509258,"median":-34.536978,"eighty":116.907582,"marketCap":16879976635},{"date":"2022-09-02","current":307.488024,"twenty":-166.509258,"median":-34.536978,"eighty":117.883617,"marketCap":16625877437},{"date":"2022-09-09","current":318.773561,"twenty":-166.509258,"median":-34.536978,"eighty":141.162306,"marketCap":17236086460},{"date":"2022-09-16","current":302.58276,"twenty":-166.509258,"median":-34.536978,"eighty":148.167383,"marketCap":16360649808},{"date":"2022-09-23","current":291.022801,"twenty":-166.509258,"median":-34.536978,"eighty":150.289725,"marketCap":15735602876},{"date":"2022-09-30","current":290.782684,"twenty":-166.509258,"median":-34.536978,"eighty":152.726136,"marketCap":15722619705},{"date":"2022-10-07","current":302.376944,"twenty":-166.509258,"median":-34.536978,"eighty":167.017841,"marketCap":16349521376},{"date":"2022-10-14","current":299.289715,"twenty":-166.509258,"median":-34.536978,"eighty":168.933976,"marketCap":16182594895},{"date":"2022-10-21","current":308.757218,"twenty":-166.509258,"median":-34.536978,"eighty":170.628042,"marketCap":16694502768},{"date":"2022-10-28","current":192.178834,"twenty":-166.509258,"median":-34.536978,"eighty":175.146289,"marketCap":16126110354},{"date":"2022-11-04","current":182.699459,"twenty":-166.509258,"median":-34.536978,"eighty":176.471621,"marketCap":15330676998},{"date":"2022-11-11","current":181.968573,"twenty":-166.509258,"median":-34.536978,"eighty":178.346579,"marketCap":15269346856},{"date":"2022-11-18","current":195.589638,"twenty":-166.509258,"median":-34.536978,"eighty":182.260927,"marketCap":16412317683},{"date":"2022-11-25","current":214.659129,"twenty":-166.509258,"median":-34.536978,"eighty":187.341695,"marketCap":18012476841},{"date":"2022-12-02","current":233.795065,"twenty":-166.509258,"median":-34.536978,"eighty":190.997361,"marketCap":19618211467},{"date":"2022-12-09","current":226.641237,"twenty":-166.509258,"median":-34.536978,"eighty":192.536436,"marketCap":19017919471},{"date":"2022-12-16","current":240.594523,"twenty":-166.509258,"median":-34.14536,"eighty":193.90401,"marketCap":20188767636},{"date":"2022-12-23","current":231.093,"twenty":-166.509258,"median":-33.835795,"eighty":195.798534,"marketCap":19391475791},{"date":"2022-12-30","current":229.210413,"twenty":-166.509258,"median":15.910621,"eighty":196.943179,"marketCap":19233504213},{"date":"2023-01-06","current":240.771708,"twenty":-166.509258,"median":15.99843,"eighty":199.747589,"marketCap":20203635549},{"date":"2023-01-13","current":249.653085,"twenty":-166.509258,"median":16.07919,"eighty":201.466427,"marketCap":20948889698},{"date":"2023-01-20","current":245.289915,"twenty":-166.509258,"median":16.188691,"eighty":202.812136,"marketCap":20582767336},{"date":"2023-01-27","current":259.730459,"twenty":-166.509258,"median":16.239185,"eighty":206.755441,"marketCap":21794502262},{"date":"2023-02-03","current":248.501386,"twenty":-166.509258,"median":16.333756,"eighty":220.240444,"marketCap":20852248263},{"date":"2023-02-10","current":242.432813,"twenty":-166.509258,"median":16.413891,"eighty":226.49506,"marketCap":20343022235},{"date":"2023-02-17","current":239.885785,"twenty":-166.509258,"median":16.442734,"eighty":229.440754,"marketCap":20129295983},{"date":"2023-02-24","current":226.065387,"twenty":-166.509258,"median":16.476957,"eighty":230.229225,"marketCap":18969598754},{"date":"2023-03-03","current":133.346847,"twenty":-166.509258,"median":16.516158,"eighty":230.229225,"marketCap":18876712940},{"date":"2023-03-10","current":119.234744,"twenty":-166.509258,"median":16.567292,"eighty":230.229225,"marketCap":16878989664},{"date":"2023-03-17","current":120.789579,"twenty":-166.509258,"median":16.617476,"eighty":230.229225,"marketCap":17099093629},{"date":"2023-03-24","current":119.564159,"twenty":-166.509258,"median":16.650384,"eighty":230.229225,"marketCap":16925621860},{"date":"2023-03-31","current":128.128926,"twenty":-166.445258,"median":16.685656,"eighty":229.9413,"marketCap":18138058956},{"date":"2023-04-06","current":127.246097,"twenty":-166.445258,"median":16.720301,"eighty":229.9413,"marketCap":18013084670},{"date":"2023-04-14","current":129.578349,"twenty":-166.509258,"median":16.77077,"eighty":230.229225,"marketCap":18343240618},{"date":"2023-04-21","current":127.575511,"twenty":-166.509258,"median":16.817229,"eighty":230.229225,"marketCap":18059716866},{"date":"2023-04-28","current":242.180022,"twenty":-166.509258,"median":16.855933,"eighty":231.407502,"marketCap":17343722249},{"date":"2023-05-05","current":250.17182,"twenty":-166.509258,"median":16.91578,"eighty":235.380867,"marketCap":17916054913},{"date":"2023-05-12","current":250.014562,"twenty":-166.573259,"median":16.941683,"eighty":237.019824,"marketCap":17904792857},{"date":"2023-05-19","current":241.732289,"twenty":-166.637259,"median":16.967171,"eighty":239.8282,"marketCap":17311657880},{"date":"2023-05-26","current":232.558885,"twenty":-166.637259,"median":17.014711,"eighty":240.585664,"marketCap":16654704583},{"date":"2023-05-30","current":231.916747,"twenty":-166.637259,"median":17.029662,"eighty":240.585664,"marketCap":16608717852},{"date":"2023-06-09","current":241.810918,"twenty":-166.73726,"median":17.061278,"eighty":241.008901,"marketCap":17317288908},{"date":"2023-06-16","current":251.194,"twenty":-166.74926,"median":17.112883,"eighty":241.385297,"marketCap":17989258281},{"date":"2023-06-23","current":250.591176,"twenty":-166.76126,"median":17.196104,"eighty":241.856963,"marketCap":17946087064},{"date":"2023-06-30","current":233.08308,"twenty":-166.76126,"median":17.241,"eighty":242.23058,"marketCap":16692244772},{"date":"2023-07-07","current":224.355242,"twenty":-166.76126,"median":17.308262,"eighty":242.23058,"marketCap":16067200635},{"date":"2023-07-14","current":224.643549,"twenty":-166.76126,"median":17.371372,"eighty":242.23058,"marketCap":16087847738},{"date":"2023-07-21","current":229.439928,"twenty":-166.76126,"median":17.48024,"eighty":242.23058,"marketCap":16431340462},{"date":"2023-07-28","current":226.871375,"twenty":-166.76126,"median":17.641098,"eighty":242.23058,"marketCap":16247393539},{"date":"2023-08-04","current":165.119407,"twenty":-166.76126,"median":17.695247,"eighty":242.23058,"marketCap":16510454583},{"date":"2023-08-11","current":171.085084,"twenty":-166.76126,"median":17.746561,"eighty":242.23058,"marketCap":17106968613},{"date":"2023-08-18","current":168.243389,"twenty":-166.76126,"median":17.778035,"eighty":242.23058,"marketCap":16822824706},{"date":"2023-08-25","current":175.281759,"twenty":-166.76126,"median":17.843539,"eighty":242.23058,"marketCap":17526598357},{"date":"2023-09-01","current":171.969585,"twenty":-166.76126,"median":17.901573,"eighty":242.23058,"marketCap":17195410756},{"date":"2023-09-08","current":170.162944,"twenty":-166.76126,"median":18.020515,"eighty":242.23058,"marketCap":17014762974},{"date":"2023-09-15","current":165.006492,"twenty":-166.76126,"median":18.09038,"eighty":242.23058,"marketCap":16499164096},{"date":"2023-09-22","current":162.352988,"twenty":-166.76126,"median":18.138595,"eighty":242.23058,"marketCap":16233837666},{"date":"2023-09-29","current":167.961101,"twenty":-166.76126,"median":18.255988,"eighty":242.23058,"marketCap":16794598490},{"date":"2023-10-06","current":164.272544,"twenty":-166.76126,"median":18.295251,"eighty":242.23058,"marketCap":16425775935},{"date":"2023-10-13","current":162.861106,"twenty":-166.76126,"median":18.372948,"eighty":242.23058,"marketCap":16284644855},{"date":"2023-10-20","current":155.427533,"twenty":-166.76126,"median":18.480739,"eighty":242.23058,"marketCap":15541354502},{"date":"2023-10-27","current":154.260745,"twenty":-166.76126,"median":18.544458,"eighty":242.382255,"marketCap":15424686142},{"date":"2023-11-03","current":102.060294,"twenty":-166.76126,"median":18.649124,"eighty":242.382255,"marketCap":15005006530},{"date":"2023-11-10","current":107.264835,"twenty":-166.76126,"median":18.746862,"eighty":242.382255,"marketCap":15770183276},{"date":"2023-11-17","current":111.736338,"twenty":-166.76126,"median":18.837592,"eighty":242.382255,"marketCap":16427588192},{"date":"2023-11-24","current":112.991947,"twenty":-166.76126,"median":18.922633,"eighty":242.382255,"marketCap":16612189000},{"date":"2023-12-01","current":116.69471,"twenty":-166.76126,"median":18.980092,"eighty":242.382255,"marketCap":17156573014},{"date":"2023-12-08","current":121.64027,"twenty":-166.76126,"median":19.115548,"eighty":242.331697,"marketCap":17883674154},{"date":"2023-12-15","current":125.073975,"twenty":-166.76126,"median":19.224871,"eighty":242.331697,"marketCap":18388500853},{"date":"2023-12-22","current":121.922141,"twenty":-166.76126,"median":19.421383,"eighty":242.331697,"marketCap":17925115152},{"date":"2023-12-29","current":124.446171,"twenty":-166.76126,"median":97.655587,"eighty":242.382255,"marketCap":18296200449},{"date":"2024-01-05","current":125.21491,"twenty":-166.76126,"median":106.724665,"eighty":242.432813,"marketCap":18409221351},{"date":"2024-01-12","current":122.998377,"twenty":-166.76126,"median":107.662485,"eighty":242.432813,"marketCap":18083344416},{"date":"2024-01-19","current":118.552498,"twenty":-166.79726,"median":109.532617,"eighty":242.575773,"marketCap":17429706862},{"date":"2024-01-26","current":116.91252,"twenty":-166.76126,"median":110.397223,"eighty":242.432813,"marketCap":17188595603},{"date":"2024-02-02","current":113.696625,"twenty":-166.76126,"median":111.153724,"eighty":242.432813,"marketCap":16715791494},{"date":"2024-02-09","current":112.940697,"twenty":-166.76126,"median":111.821225,"eighty":242.432813,"marketCap":16604654273},{"date":"2024-02-16","current":113.132882,"twenty":-166.76126,"median":112.099749,"eighty":242.432813,"marketCap":16632909499},{"date":"2024-02-23","current":101.214924,"twenty":-166.70126,"median":112.294622,"eighty":242.432813,"marketCap":16968175915},{"date":"2024-03-01","current":97.103598,"twenty":-165.901253,"median":112.199476,"eighty":242.382255,"marketCap":16278932666},{"date":"2024-03-08","current":96.664673,"twenty":-164.837246,"median":112.199476,"eighty":242.382255,"marketCap":16205349173},{"date":"2024-03-15","current":94.976502,"twenty":-164.11324,"median":112.199476,"eighty":242.382255,"marketCap":15922335740},{"date":"2024-03-22","current":94.661377,"twenty":-162.221226,"median":112.199476,"eighty":242.382255,"marketCap":15869506566},{"date":"2024-03-28","current":99.72589,"twenty":-162.081225,"median":112.199476,"eighty":242.382255,"marketCap":16718546865},{"date":"2024-04-05","current":97.790121,"twenty":-160.981216,"median":112.294622,"eighty":242.432813,"marketCap":16394024795},{"date":"2024-04-12","current":103.533211,"twenty":-131.648601,"median":112.294622,"eighty":242.432813,"marketCap":17356825158},{"date":"2024-04-19","current":101.959724,"twenty":-125.404689,"median":112.294622,"eighty":242.432813,"marketCap":17093037852},{"date":"2024-04-26","current":75.899547,"twenty":-124.450186,"median":112.199476,"eighty":242.382255,"marketCap":15593941332},{"date":"2024-05-03","current":77.447263,"twenty":-123.068927,"median":112.199476,"eighty":242.382255,"marketCap":15911927491},{"date":"2024-05-10","current":75.524945,"twenty":-121.619256,"median":112.199476,"eighty":242.382255,"marketCap":15516977501},{"date":"2024-05-17","current":71.135034,"twenty":-119.850332,"median":112.199476,"eighty":242.382255,"marketCap":14615048436},{"date":"2024-05-24","current":70.146149,"twenty":-118.560287,"median":112.199476,"eighty":242.382255,"marketCap":14411877047},{"date":"2024-05-31","current":68.833797,"twenty":-117.48525,"median":112.199476,"eighty":242.382255,"marketCap":14142247727},{"date":"2024-06-07","current":74.720898,"twenty":-116.644766,"median":112.199476,"eighty":242.382255,"marketCap":15351782072},{"date":"2024-06-14","current":77.853908,"twenty":-111.266324,"median":112.294622,"eighty":242.432813,"marketCap":15995474604},{"date":"2024-06-21","current":78.288278,"twenty":-109.731954,"median":112.389767,"eighty":242.575773,"marketCap":16084718112},{"date":"2024-06-28","current":77.170006,"twenty":-106.985723,"median":112.453746,"eighty":243.004654,"marketCap":15854963550},{"date":"2024-07-05","current":74.836422,"twenty":-105.324301,"median":112.453746,"eighty":243.004654,"marketCap":15375517047},{"date":"2024-07-12","current":77.548924,"twenty":15.962481,"median":112.453746,"eighty":243.004654,"marketCap":15932814269},{"date":"2024-07-15","current":78.574777,"twenty":15.978924,"median":112.453746,"eighty":243.004654,"marketCap":16143580851},{"date":"2024-08-02","current":78.205101,"twenty":16.215911,"median":112.851011,"eighty":244.594819,"marketCap":16067628929},{"date":"2024-08-09","current":65.219671,"twenty":16.277249,"median":112.851011,"eighty":244.594819,"marketCap":16734650053},{"date":"2024-08-16","current":66.1694,"twenty":16.362887,"median":112.851011,"eighty":244.594819,"marketCap":16978340065},{"date":"2024-08-23","current":66.792659,"twenty":16.42422,"median":112.851011,"eighty":244.594819,"marketCap":17138261636},{"date":"2024-08-30","current":67.794327,"twenty":16.45237,"median":112.851011,"eighty":244.594819,"marketCap":17395278446},{"date":"2024-09-06","current":63.156978,"twenty":16.479702,"median":112.851011,"eighty":244.594819,"marketCap":16205385808},{"date":"2024-09-13","current":62.607916,"twenty":16.537344,"median":112.851011,"eighty":244.594819,"marketCap":16064502520},{"date":"2024-09-20","current":52.98449,"twenty":16.577992,"median":112.851011,"eighty":244.594819,"marketCap":13595237319},{"date":"2024-09-27","current":52.116378,"twenty":16.619251,"median":112.851011,"eighty":244.594819,"marketCap":13372489417},{"date":"2024-10-04","current":50.573069,"twenty":16.6558,"median":112.851011,"eighty":244.594819,"marketCap":12976493147},{"date":"2024-10-11","current":51.827008,"twenty":16.697708,"median":112.851011,"eighty":244.594819,"marketCap":13298240116},{"date":"2024-10-18","current":51.545057,"twenty":16.760117,"median":112.851011,"eighty":244.594819,"marketCap":13225894644},{"date":"2024-10-25","current":52.227675,"twenty":16.799788,"median":112.851011,"eighty":244.594819,"marketCap":13401046840},{"date":"2024-10-31","current":39.424418,"twenty":16.832825,"median":112.851011,"eighty":244.594819,"marketCap":12706135252},{"date":"2024-11-08","current":39.584187,"twenty":16.900012,"median":112.851577,"eighty":244.597655,"marketCap":12757627091},{"date":"2024-11-15","current":38.791793,"twenty":16.930391,"median":112.851577,"eighty":244.597655,"marketCap":12502245849},{"date":"2024-11-22","current":37.520416,"twenty":16.956385,"median":112.851577,"eighty":244.597655,"marketCap":12092492365},{"date":"2024-11-29","current":39.046069,"twenty":16.983395,"median":112.851577,"eighty":244.597655,"marketCap":12584196546},{"date":"2024-12-06","current":39.122943,"twenty":17.042364,"median":112.851577,"eighty":244.597655,"marketCap":12608972338},{"date":"2024-12-13","current":39.182077,"twenty":17.063524,"median":112.851577,"eighty":244.597655,"marketCap":12628030640},{"date":"2024-12-20","current":38.43699,"twenty":17.120949,"median":112.851577,"eighty":244.597655,"marketCap":12387896040},{"date":"2024-12-27","current":39.631494,"twenty":17.201205,"median":112.851577,"eighty":244.597655,"marketCap":12772873732},{"date":"2025-01-03","current":39.318084,"twenty":17.236838,"median":112.851577,"eighty":244.597655,"marketCap":12671864733},{"date":"2025-01-10","current":40.435714,"twenty":17.313842,"median":112.852143,"eighty":244.60049,"marketCap":13032066634},{"date":"2025-01-17","current":36.219472,"twenty":17.376382,"median":112.852143,"eighty":244.60049,"marketCap":11673209730},{"date":"2025-01-24","current":36.77533,"twenty":17.466817,"median":112.852143,"eighty":244.60049,"marketCap":11852357765},{"date":"2025-01-31","current":37.774691,"twenty":17.638541,"median":112.852143,"eighty":244.60049,"marketCap":12174443062},{"date":"2025-02-07","current":38.046707,"twenty":17.688324,"median":112.852143,"eighty":244.60049,"marketCap":12262111249},{"date":"2025-02-14","current":38.094014,"twenty":17.743365,"median":112.852143,"eighty":244.60049,"marketCap":12277357890},{"date":"2025-02-21","current":30.715125,"twenty":17.776197,"median":112.852143,"eighty":244.60049,"marketCap":13111027516},{"date":"2025-02-28","current":30.891957,"twenty":17.826301,"median":112.852143,"eighty":244.60049,"marketCap":13186509834},{"date":"2025-03-07","current":31.826045,"twenty":17.900998,"median":112.870795,"eighty":244.603325,"marketCap":13585233872},{"date":"2025-03-14","current":31.553417,"twenty":18.033156,"median":112.870795,"eighty":244.603325,"marketCap":13468859871},{"date":"2025-03-21","current":32.000349,"twenty":18.097039,"median":112.870795,"eighty":244.603325,"marketCap":13659636923},{"date":"2025-03-28","current":32.550076,"twenty":18.156695,"median":112.870795,"eighty":244.603325,"marketCap":13894292697},{"date":"2025-04-04","current":30.158988,"twenty":18.272189,"median":112.870795,"eighty":244.603325,"marketCap":12873635468},{"date":"2025-04-11","current":25.171224,"twenty":18.291457,"median":112.852143,"eighty":244.60049,"marketCap":10744563568},{"date":"2025-04-17","current":26.423199,"twenty":18.323094,"median":112.852143,"eighty":244.60049,"marketCap":11278980279}],"updateTime":1745156419538}}}